Developing Monoclonal Antibodies to Transform the Future of Sickle Cell Care
We are an early stage biotech company that has created a monoclonal antibody(s) for the treatment of Sickle Cell Disease. We are targeting a receptor that has ubiquitous possibilities. Our goal is to provide the global village access to compounds that improve patients' quality of life and outcomes through our novel scientific technology. D-10 strives to make our monoclonal antibody(s) available at an affordable price for the patient population that we serve.
Pioneering Affordable Innovations for Sickle Cell Disease
D-10 is developing a novel therapy to treat sickle cell disease, which is an orphan indication with limited and sometimes life-threatening treatments available today.
D-10 Therapeutics aims to develop a treatment that prevents damage to the blood vessels by preventing the Sickle cells from binding to blood vessel walls by blocking the receptors that cause the Sickle cells to adhere to the blood vessels. This treatment would also induce the relaxation of smooth muscle cells within the blood vessels which in turn widens the space for blood cells to travel.
By delivering a disease-modifying treatment, D-10 is changing the course of Sickle Cell Disease treatment and presenting a solution to a multibillion-dollar market.
Market Opportunity: Sickle Cell Disease (SCD)
Disease Impact
A chronic genetic condition where rigid red blood cells obstruct flow, leading to severe pain crises, organ failure, and significantly reduced lifespan.
Commercial Potential
The global SCD market represents a multi-billion dollar opportunity, encompassing over 20 million patients worldwide. D-10 identifies and targets significant clinical white spaces to address entrenched unmet needs within this underserved orphan disease segment.
D-10 Solution
Our monoclonal antibody (mAb) program focuses on targeted intervention to minimize morbidity and fundamentally enhance patient quality of life.
Research Status
Assets are in the discovery and preclinical phases, undergoing rigorous molecular validation to ensure therapeutic efficacy ahead of clinical advancement.
Therapeutic Platform
Innovative Monoclonal Antibody Engineering
D-10 Therapeutics utilizes proprietary monoclonal antibody platforms to target the underlying mechanisms of Sickle Cell Disease, ensuring both efficacy and accessibility through technical ingenuity.
Therapeutic Pipeline
D-10 Therapeutics is advancing high-impact antibody therapies in the discovery and preclinical stages for Sickle Cell Disease (SCD) and neurodegenerative conditions.
Deep Expertise in Drug Development & Market Access
OUR TEAM
Combined 100+ Years of Experience across Oncology, CNS, and Hematology.
CEO & Founder, Head of R&D
Dr. Louis Jefferson
Seasoned senior leader with over 30 years of global experience in clinical research at top pharmaceutical companies including Pfizer, Amgen, and Bayer. Deep expertise across oncology, CNS, rare diseases, and hematology. Recognized authority in sickle cell disease biology and pharmacology, G-protein–coupled receptors, and drug discovery.
CSO & COO Co-Founder
Dr. Metasebya Solomon
Ph.D. in Biomedical Engineering with over 10 years of experience in biomedical R&D. Expert in bridging academic research with industry, leading scientific collaborations in sickle cell disease translational research. Recognized for fostering cross-sector innovation and driving impactful partnerships between academia and biotech.
SCIENTIFIC & STRATEGIC ADVISORS
Senior Business Advisor
Dr. Clifford M. Samuel
Expert in pharmaceutical commercialization in emerging markets. Advises D-10 on access, pricing, and strategic partnerships. Recognized for driving market entry strategies and establishing high-impact collaborations to maximize therapeutic reach worldwide.
Scientific Advisor
Dr. Julie Makani
Professor of Hematology and global sickle cell disease expert leading research across Africa. Supports D-10's clinical trial and access strategy in low- and middle-income countries (LMICs), health system integration, and equitable access to innovative therapies.
Contact & Support
Get in Touch with D-10
Physical Address: 1124 West Carson,
MRL Building, 3rd Floor
Torrance, CA 90502
Reach out to discuss our monoclonal antibody research or Sickle Cell Disease treatment innovations. We're dedicated to improving patient quality of life worldwide.